L-Glutathione (GSH): The Cellular Master Antioxidant Tripeptide

Research summary. L-Glutathione (γ-glutamyl-cysteinyl-glycine, GSH) is a tripeptide composed of glutamate, cysteine, and glycine. It is the most abundant non-protein thiol in mammalian cells and the principal endogenous antioxidant in the cytosol, mitochondria, and nucleus. Glutathione is biosynthesised in essentially all nucleated cells through a two-step ATP-dependent pathway and exists in dynamic equilibrium between its reduced form (GSH) and its oxidised disulfide form (GSSG). The GSH/GSSG ratio is one of the most widely used biochemical markers of cellular redox state.

Molecular profile

• Sequence: γ-Glu-Cys-Gly (note the unusual γ-glutamyl peptide bond, which renders glutathione resistant to most proteases that cleave standard α-peptide bonds)
• Molecular formula: C₁₀H₁₇N₃O₆S
• Molecular weight: ~307.3 g/mol
• PubChem CID: 124886
• CAS Number: 70-18-8
• Synonyms: GSH, reduced glutathione, γ-L-glutamyl-L-cysteinylglycine

The γ-glutamyl bond between the glutamate γ-carboxyl group and the cysteine α-amino group is critical to glutathione's stability in the gastrointestinal and circulatory environments — it is not cleaved by most aminopeptidases — but does require the specialised enzyme γ-glutamyl transpeptidase (GGT) for breakdown.

Mechanism of action

Glutathione's principal biochemical activities centre on the cysteine thiol group:

• Direct radical scavenging. GSH neutralises reactive oxygen species (hydroxyl radical, peroxynitrite) and reactive nitrogen species through one-electron transfers, with the resulting glutathione thiyl radical (GS·) recombining to form GSSG.
• Glutathione peroxidase substrate. GSH serves as the reducing substrate for the glutathione peroxidase family of selenoenzymes, which detoxify hydrogen peroxide and lipid peroxides.
• Glutathione S-transferase substrate. Phase II detoxification of xenobiotics involves GSH conjugation through the GST enzyme family — a major hepatic detoxification pathway and the rationale for glutathione's role in paracetamol overdose toxicology.
• Protein S-glutathionylation. Reversible covalent attachment of GSH to protein cysteine residues is a regulated post-translational modification with effects on protein function and signalling.
• Cofactor for selenoenzymes and other thiol-dependent enzymes. GSH supports a broad set of redox-sensitive catalytic activities.

The GSH/GSSG ratio in cytosol typically exceeds 100:1 under healthy conditions and falls during oxidative stress, providing a quantitative readout of redox state.

Age-related decline and disease association

A consistent observation in the GSH literature is that intracellular glutathione concentrations decline with age across multiple tissues, beginning in middle age in both rodents and humans. The decline tracks with reduced expression of GCLC (the rate-limiting biosynthetic enzyme γ-glutamylcysteine ligase catalytic subunit) rather than with increased degradation. Reduced GSH has been associated with:

• Neurodegenerative disease. Reduced GSH is documented in Parkinson's disease (notably in substantia nigra), Alzheimer's disease, and ALS, where it has been hypothesised to contribute to vulnerability of dopaminergic and other neuron populations to oxidative stress.
• Eye disease. GSH depletion has been reported in cataract, age-related macular degeneration, and diabetic retinopathy.
• Liver disease. Hepatic GSH depletion is central to paracetamol-induced liver injury and contributes to the pathophysiology of alcoholic and non-alcoholic liver disease.
• HIV. Systemic GSH depletion has been documented in HIV infection and contributes to oxidative stress in T-lymphocyte populations.

Bioavailability considerations

A long-standing practical issue with glutathione supplementation is that oral GSH is poorly bioavailable. Oral administration leads to GGT-mediated cleavage in the GI tract and limited intact peptide reaching systemic circulation. Strategies that have been investigated to circumvent this:

• Precursor supplementation. N-acetyl cysteine (NAC) provides cysteine, the rate-limiting amino acid in GSH biosynthesis. NAC is widely used clinically (notably as the antidote in paracetamol overdose) and can support GSH synthesis where biosynthetic capacity is intact, but is less effective in older subjects in whom biosynthetic enzyme expression has declined.
• Liposomal and sublingual formulations. Designed to bypass first-pass GI metabolism with limited validation of relative bioavailability.
• Intravenous and inhaled administration. Used in selected research and clinical contexts.

Preclinical and clinical research highlights

Paracetamol toxicology. Hepatic GSH depletion is the central event in paracetamol-induced liver injury, and intravenous N-acetylcysteine repletion is the standard antidote, with a body of clinical evidence spanning decades. This is one of the best-validated examples of glutathione-based clinical pharmacology.

Parkinson's disease research. Studies of intravenous GSH in Parkinson's disease have produced mixed results — some short-term improvements in motor symptoms reported in small studies, larger trials showing more modest effects.

Cystic fibrosis. Inhaled glutathione has been investigated in cystic fibrosis research as a strategy to address oxidative stress in airway secretions.

Cancer chemotherapy adjunct. GSH has been studied as a possible mitigator of cisplatin and other chemotherapy toxicities in supportive-care research.

Skin and dermatology. Topical and intravenous glutathione has been studied in melanogenesis modulation contexts. Systemic glutathione "skin-lightening" has been the subject of regulatory caution in several jurisdictions.

Current research status

L-Glutathione is not a single regulated product but rather an endogenous metabolite available across multiple regulatory contexts: as a research-grade reagent, as a dietary-supplement ingredient (with limited efficacy claims), and as an injectable preparation in selected jurisdictions. NAC (the precursor) is approved as a prescription pharmaceutical for paracetamol overdose and as a respiratory mucolytic in some jurisdictions.

Key takeaways for researchers

• Glutathione (GSH) is the most abundant cellular non-protein thiol and the principal cytosolic antioxidant.
• Its activity centres on the cysteine thiol; the GSH/GSSG ratio is a key marker of cellular redox state.
• Oral bioavailability is poor due to GGT-mediated cleavage; alternative routes include intravenous, inhaled, liposomal, and precursor (NAC) supplementation.
• Reduced GSH has been documented across neurodegenerative, hepatic, ocular, and infectious disease contexts.
• N-acetylcysteine is the validated clinical precursor strategy, particularly in paracetamol toxicology.
• L-Glutathione is widely available as a research reagent and supplement; it is not a defined therapeutic in most regulatory contexts.

References

1. Meister A, Anderson ME. Glutathione. Annual Review of Biochemistry. 1983;52:711–760.

---

This article is provided for educational and research purposes only. L-Glutathione is an endogenous metabolite. While it is widely available as a research-grade compound and dietary supplement, it is not generally a defined prescription pharmaceutical and is not intended for diagnosis, treatment, cure, or prevention of any disease or condition outside of approved clinical contexts (such as N-acetylcysteine use in paracetamol overdose under qualified clinical supervision). All research work involving this compound should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable institutional and regulatory requirements.